Tenderwize
Back to tender search

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2026 · 131 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschl. nicht exkl. Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Modells zum WS Aflibercept (ATC-Code nach WHO: S01LA05; ausgen. 114,3 mg/ml) als Injektionsl. in einer Durchstechflasche

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial.
  • Open-House participation model: any interested pharmaceutical company may join during the participation period if it meets and accepts the participation conditions.
Show full summary

This is an Open-House supply arrangement for non-exclusive rebate agreements under §130a(8) SGB V for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. The procedure is open to all eligible pharmaceutical companies during the participation period, with no individual negotiations and no exclusivity. The notice indicates electronic communication via DTVP, but participation documents must be obtained from the project room after access approval. The contract ends no later than 31.12.2026, and the purchase volume is unknown with no minimum quantity guaranteed.

Risks

The exact submission process is unclear because the structured data says electronic submission is not allowed, while th...

Demand and purchase volume are explicitly unknown, and no minimum quantity is guaranteed.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company or its local representative may participate only if it itself qualifies as a pharmaceutical company for the offered product.
  • No Russia-related connection within the meaning of Article 5k of Regulation (EU) No 833/2014, as amended by Regulation (EU) 2022/576, must be declared using the provided...

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for Aflibercept injectable solution in vial

Single lot covering non-exclusive rebate agreements for Aflibercept (ATC S01LA05, excluding 114.3 mg/ml) as an injectable solution in a vial. This is an Open-House model with no exclusivity, no individual negotiations, and unknown demand/volume. Place of performance is Dresden, Germany, with performance also referenced for Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Dec 2025 - Dec 2026

Category

Pharmaceutical products

Deadline

Deadline Dec 31, 2026

Procurement Details

Publication date
11 Nov 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
750728-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3